News Releases Keyword Search Year None2023202220212020201920182017201620152014 Sep 13, 2023 Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock Sep 12, 2023 Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock Sep 12, 2023 Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease Sep 06, 2023 Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences Aug 10, 2023 Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress Jun 08, 2023 Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM) May 31, 2023 Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease May 23, 2023 Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD) May 19, 2023 Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) May 09, 2023 Rocket Pharmaceuticals Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM) May 04, 2023 Rocket Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Progress May 03, 2023 Rocket Pharmaceuticals to Participate in the Bank of America Securities 2023 Healthcare Conference Apr 11, 2023 Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences Apr 04, 2023 Rocket Pharmaceuticals Announces Leadership Expansion to Support Company on Evolution Towards Commercial Stage Mar 01, 2023 Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference Feb 27, 2023 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results Feb 09, 2023 Rocket Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference Feb 07, 2023 Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease Jan 09, 2023 Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease Jan 03, 2023 Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference Print Page RSS E-mail Alerts Contact
Keyword Search Year None2023202220212020201920182017201620152014 Sep 13, 2023 Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock Sep 12, 2023 Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock Sep 12, 2023 Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease Sep 06, 2023 Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences Aug 10, 2023 Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress Jun 08, 2023 Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM) May 31, 2023 Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease May 23, 2023 Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD) May 19, 2023 Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) May 09, 2023 Rocket Pharmaceuticals Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM) May 04, 2023 Rocket Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Progress May 03, 2023 Rocket Pharmaceuticals to Participate in the Bank of America Securities 2023 Healthcare Conference Apr 11, 2023 Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences Apr 04, 2023 Rocket Pharmaceuticals Announces Leadership Expansion to Support Company on Evolution Towards Commercial Stage Mar 01, 2023 Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference Feb 27, 2023 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results Feb 09, 2023 Rocket Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference Feb 07, 2023 Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease Jan 09, 2023 Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease Jan 03, 2023 Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
Sep 12, 2023 Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease
Aug 10, 2023 Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress
Jun 08, 2023 Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
May 31, 2023 Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease
May 23, 2023 Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD)
May 19, 2023 Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
May 09, 2023 Rocket Pharmaceuticals Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
May 04, 2023 Rocket Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Progress
May 03, 2023 Rocket Pharmaceuticals to Participate in the Bank of America Securities 2023 Healthcare Conference
Apr 04, 2023 Rocket Pharmaceuticals Announces Leadership Expansion to Support Company on Evolution Towards Commercial Stage
Feb 27, 2023 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results
Feb 07, 2023 Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease
Jan 09, 2023 Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease
